Triple Negative Breast Cancer Pipeline Insight A growing number of innovative therapies for triple-negative breast cancer (TNBC) – including TECENTRIQ (Hoffmann-La Roche), IPI-549 (Infinity Pharmaceuticals), Leronlimab (CytoDyn), MDNA11 (Medicenna Therapeutics),
Triple-Negative Breast Cancer Clinical Trial Arena Broadens With 170+ Pipeline Candidates, Reports DelveInsight
Colorectal Cancer Competitive Landscape Leading companies active in the colorectal cancer space include Nektar Therapeutics, ALX Oncology Inc., Processa Pharmaceuticals, Guojian Pharmaceutical, Gritstone Bio, Daiichi Sankyo, Novartis Pharmaceuticals, Shanghai Henlius
Muscle Invasive Bladder Cancer Competitive Landscape Leading companies operating in the Muscle Invasive Bladder Cancer (MIBC) space include Merck Sharp & Dohme LLC, Aura Biosciences, Janssen Research & Development, LLC,
Severe Asthma Clinical Trial Prominent companies actively shaping the severe asthma treatment space include Kinaset Therapeutics, Bio-Thera Solutions, CSPC ZhongQi Pharmaceutical Technology, AB Science, GlaxoSmithKline, Oneness Biotech, Biosion, Lanier Biotherapeutics,
Obesity Clinical Trial Major companies active in the obesity space include Pfizer, Biolingus, Regor Pharmaceuticals, Zealand Pharma, Sirnaomics, Innovent Biologics,
In just 5 minutes, any AI can be upgraded to a scientific discoverer. On February 14th, 2026, the original Chinese
DelveInsight’s, “B-cell Lymphoma Pipeline Insight, 2025” report provides comprehensive insights about 295+ companies and 300+ pipeline drugs in B-cell Lymphoma
DelveInsight’s, “EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Pipeline Insight 2025” report provides comprehensive insights about 25+ companies and
DelveInsight’s “Glioblastoma Pipeline Insight, 2025” report provides comprehensive insights about 200+ companies and 220+ pipeline drugs in Glioblastoma pipeline landscape.
DelveInsight’s “Gastric Cancer Pipeline Insight 2025” report provides comprehensive insights about 200+ companies and 220+ pipeline drugs in the Gastric
